2022
DOI: 10.1038/s41698-022-00289-1
|View full text |Cite
|
Sign up to set email alerts
|

Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case

Abstract: Little is known about the complexity and plasticity of circulating tumor cell (CTC) biology in different compartments of the fluid microenvironment during tumor metastasis. Here we integrated phenomics, genomics, and targeted proteomics to characterize CTC phenotypic and genotypic heterogeneity in paired peripheral blood (PB) and bone marrow aspirate (BMA) from a metastatic prostate cancer patient following the rapid disease progression, using the High-Definition Single Cell Assay 3.0 (HDSCA3.0). Uniquely, we … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(6 citation statements)
references
References 48 publications
0
6
0
Order By: Relevance
“…Blood was collected from a patient diagnosed with de novo metastatic prostate cancer following castration resistance as previously described in [ 101 ]. Blood cells were plated on cell-adhesive (Marienfeld) slides and underwent immunofluorescent stained for a mixture anti-human cytokeratins 1, 4, 5 ,6, 8, 10, 13, 18 and 19, CD45, vimentin, and DAPI as previously described in [ 101 ]. Slides were imaged and analyzed as previously described in [ 101 ].…”
Section: Methodsmentioning
confidence: 99%
“…Blood was collected from a patient diagnosed with de novo metastatic prostate cancer following castration resistance as previously described in [ 101 ]. Blood cells were plated on cell-adhesive (Marienfeld) slides and underwent immunofluorescent stained for a mixture anti-human cytokeratins 1, 4, 5 ,6, 8, 10, 13, 18 and 19, CD45, vimentin, and DAPI as previously described in [ 101 ]. Slides were imaged and analyzed as previously described in [ 101 ].…”
Section: Methodsmentioning
confidence: 99%
“…Blood cells were plated on cell-adhesive (Marienfeld) slides and underwent immunofluorescent stained for a mixture anti-human cytokeratins 1,4,5,6,8,10,13,18 and 19, CD45, Vimentin, and DAPI as previously described in [88]. Slides were imaged and analyzed as previously described in [88]. b.…”
Section: Ctc Detectionmentioning
confidence: 99%
“…Blood was collected from a patient diagnosed with de novo metastatic prostate cancer following castration resistance as previously described in [88]. Blood cells were plated on cell-adhesive (Marienfeld) slides and underwent immunofluorescent stained for a mixture anti-human cytokeratins 1,4,5,6,8,10,13,18 and 19, CD45, Vimentin, and DAPI as previously described in [88]. Slides were imaged and analyzed as previously described in [88].…”
Section: Ctc Detectionmentioning
confidence: 99%
“…[46,47] In addition, vimentin is also present at the extracellular surface of endothelial cells and macrophages, [48][49][50] which could potentially appear in the blood and exhibit CD45staining. The definition of mesenchymal CTCs in our study is based on the current literature, which suggests that VIM expression is associated with mesenchymal-like properties in cancer cells, [29,[51][52][53][54][55][56][57][58] including increased motility, invasiveness, and resistance to apoptosis. However, we understand that this definition may not be specific to CTCs, as other rare circulating cells in the blood may also express VIM.…”
Section: Discussionmentioning
confidence: 99%